<DOC>
	<DOCNO>NCT02242227</DOCNO>
	<brief_summary>The primary objective trial establish non-inferiority lung function response 25 μg salmeterol , administer xinafoate salt , inhalation powder deliver hard polyethylene ( PE ) capsule via HandiHaler® 2 compare Serevent® Diskus® ( salmeterol 50 μg , administer xinafoate salt ) follow single dose inhalation patient COPD . The secondary objective characterize pharmacokinetics salmeterol inhalation powder deliver HandiHaler® 2 PE hard capsule salmeterol xinafoate deliver Serevent® Diskus® , compare safety two pharmaceutical form .</brief_summary>
	<brief_title>Efficacy , Pharmacokinetics Safety Comparison Salmeterol Inhalation Powder Administered Via HandiHaler® 2 Serevent® Diskus® Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>All patient must sign informed consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline local legislation prior studyrelated procedure , include medication washout restriction All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable* airway obstruction predose FEV1 ≤ 60 % predict normal FEV1 ≤ 70 % FVC Visits 1 2 . *The enrolment patient exacerbation within six week prior plan study entry postpone At Visit 1 , patient must demonstrate improvement FEV1 ≥ 12 % prebronchodilator value 45 minute inhalation 4 puff 100 μg salbutamol ( Sultanol® MDI ) Male female patient 40 year age old Patients must current exsmokers smoke history 10 packyears ( ( Patients never smoke cigarette must exclude ) Patients must able perform technically acceptable pulmonary function test study period require protocol Patients must able inhale medication competent manner HandiHaler® 2 device Diskus® device Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients recent history ( i.e. , six month less ) myocardial infarction Patients hospitalize heart failure ( New York Heart Association ( NYHA ) class III IV ) within past year Patients unstable life threaten cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . Patients treat basal cell carcinoma allow Patients history asthma , allergic rhinitis atopy total blood eosinophil count ≥600/mm3 Patients history life threaten pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis Patients know active tuberculosis Patients significant alcohol drug abuse within past two year Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 Patients complete pulmonary rehabilitation program six week prior Screening Visit ( Visit 1 ) patient currently pulmonary rehabilitation program maintain throughout duration study Patients regularly use daytime oxygen therapy one hour per day investigator 's opinion unable abstain use oxygen therapy Patients treat antihistamine ( H1 receptor antagonist ) , antileukotrienes leukotriene receptor antagonist asthma exclude allergic condition Patients treat cromolyn sodium nedocromil sodium within one month prior Visit 1 runin period Patients use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day Patients know hypersensitivity betaadrenergics , lactose component inhalation capsule delivery system Diskus® Pregnant nursing woman woman childbearing potential use medically approve mean contraception previous three month ( i.e . oral contraceptive , intrauterine device , diaphragm subdermal implant , e.g . : Norplant® ) Patients take investigational drug within one month six half life ( whichever great ) prior Visit 1 Patients treated oral betaadrenergics within one month prior Visit 1 runin period Patients treat theophylline preparation within one month prior Visit 1 runin period Patients treat longacting anticholinergic tiotropium ( Spiriva® ) within one month prior Visit 1 runin period Patients respiratory infection six week prior Screening Visit ( Visit 1 ) runin period . In case respiratory infection runin period latter may extend six week Patients currently participate another study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>